Abstract
Bortezomib was the first proteasome inhibitor (PI) discovered and demonstrated great efficacy in myeloma, both in vitro and in patients. However, still many patients ultimately relapse and there is the need for novel therapies. A second generation of PI have been discovered, potentially more effective ands some also orally administered. Carfilzomib is an irreversible proteasome inhibitor that showed great efficacy in clinical studies. Ixazomib is an oral compound that has been introduced recently in the therapeutic spectrum. Novel agents such as Marizomib seem promising in the fact that can also pass through the blood brain barrier and maybe effective also in CNS muyeloma. This review focus on all proteasome inhibitors available in clinics and the new ones coming soon.
Keywords: Myeloma, bortezomib, new proteasome inhibitors, carfilzomib, oprozomib.
Anti-Cancer Agents in Medicinal Chemistry
Title:Second Generation Proteasome Inhibitors in Multiple Myeloma
Volume: 17 Issue: 7
Author(s): Alessandro Gozzetti*, Giulia Papini, Veronica Candi, Corrado Zuanelli Brambilla, Santina Sirianni and Monica Bocchia
Affiliation:
- Hematology, Policlinico “Santa Maria alle Scotte”, Viale Bracci 16, 53100 Siena,Italy
Keywords: Myeloma, bortezomib, new proteasome inhibitors, carfilzomib, oprozomib.
Abstract: Bortezomib was the first proteasome inhibitor (PI) discovered and demonstrated great efficacy in myeloma, both in vitro and in patients. However, still many patients ultimately relapse and there is the need for novel therapies. A second generation of PI have been discovered, potentially more effective ands some also orally administered. Carfilzomib is an irreversible proteasome inhibitor that showed great efficacy in clinical studies. Ixazomib is an oral compound that has been introduced recently in the therapeutic spectrum. Novel agents such as Marizomib seem promising in the fact that can also pass through the blood brain barrier and maybe effective also in CNS muyeloma. This review focus on all proteasome inhibitors available in clinics and the new ones coming soon.
Export Options
About this article
Cite this article as:
Gozzetti Alessandro*, Papini Giulia, Candi Veronica, Brambilla Zuanelli Corrado, Sirianni Santina and Bocchia Monica, Second Generation Proteasome Inhibitors in Multiple Myeloma, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520616666160902101622
DOI https://dx.doi.org/10.2174/1871520616666160902101622 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry The Use of Adenoviral Vectors for Genetic Manipulation and Analysis of Primitive Hematopoietic Cells
Current Gene Therapy Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases
Current Protein & Peptide Science Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry The Evolving AML Genomic Landscape: Therapeutic Implications
Current Cancer Drug Targets IO Nation: The Rise of Immuno-Oncology
Current Pharmacogenomics and Personalized Medicine A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry BK Polyoma Virus Nephropathy in an Immunocompromised Host
New Emirates Medical Journal Predicting Hub Genes of Glioblastomas Based on a Support Vector Machine Combined with CFS Algorithms
Current Bioinformatics Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology